Trovagene receives USAN approval for "Onvansertib" as nonproprietary name
Trovagene announced the USAN Council has approved "Onvansertib" (pronounced on-van-ser-tib) as the nonproprietary (generic) name for its drug candidate, PCM-075. Onvansertib is a first-in-class, 3rd generation, highly selective, oral Polo Like Kinase 1 inhibitor designed to inhibit mitosis. August 16, 2018